ASH 2019 | Prognostic drivers in AML and MDS
Genomic sequencing studies are needed to gain a deeper understanding of the pathogenesis of myeloid malignancies. Ilaria Iacobucci, PhD, St. Jude Children’s Research Hospital, Memphis, TN, discusses the integrated genome-wide mutational/transcriptomic analysis performed on a large cohort of adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) samples to accurately define subtypes of diagnostic, prognostic and therapeutic relevance. Genome/transcriptome sequencing and gene expression analysis enabled the definition of subtypes and constellations of mutations in AML and MDS, which have prognostic significance that surpasses previous gene panel-based classifications. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up